Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs
Posted
Frank Vinluan (via MedCity News)
Roche’s Tecentriq Hybreza is a subcutaneously injectable formulation of the cancer drug Tecentriq while Ocrevus Zunovo is an injectable version of multiple sclerosis drug Ocrevus. Each is administered in minutes compared to an hour or more for infused therapies.
The post Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs appeared first on MedCity News.
